|
Clinical characteristics
|
Resistin/MCP-1
|
Resistin/RBP4
|
Visfatin/MCP-1
|
Visfatin/SFRP5
|
MCP-1/RBP4
|
Leptin/MCP-1
|
|---|
|
ρ (rho)
|
P value
|
ρ (rho)
|
P value
|
ρ (rho)
|
P value
|
ρ (rho)
|
P value
|
ρ (rho)
|
P value
|
ρ (rho)
|
P value
|
|---|
|
Fasting glucose (mmol/l)
|
0.01
|
0.88
|
− 0.47
|
<
0.0001
|
0.35
|
<
0.0001
|
0.1
|
0.29
|
0.51
|
<
0.0001
|
0.2
|
0.001
|
|
Triglycerides (mmol/l)
|
− 0.08
|
0.23
|
− 0.19
|
0.006
|
0.1
|
0.2
|
0.12
|
0.2
|
0.09
|
0.16
|
0.08
|
0.17
|
|
Total cholesterol (mmol/l)
|
− 0.07
|
0.3
|
− 0.02
|
0.8
|
− 0.03
|
0.7
|
− 0.09
|
0.32
|
0.05
|
0.48
|
0.12
|
0.55
|
|
HDL-C (mmol/l)
|
− 0.004
|
0.95
|
0.12
|
0.08
|
− 0.1
|
0.24
|
− 0.17
|
0.08
|
− 0.07
|
0.28
|
− 0.03
|
0.66
|
|
LDL-C (mmol/l)
|
0.008
|
0.9
|
0.06
|
0.4
|
− 0.02
|
0.78
|
− 0.22
|
0.019
|
0.01
|
0.8
|
0.13
|
0.035
|
|
Glycosylated hemoglobin (HbA1c) (%)
|
− 0.04
|
0.58
|
0.43
|
< 0.0001
|
0.23
|
0.004
|
0.03
|
0.7
|
0.44
|
<
0.0001
|
0.17
|
0.008
|
|
Insulin (mIU/l)
|
0.05
|
0.43
|
0.08
|
0.24
|
− 0.04
|
0.61
|
0.03
|
0.79
|
− 0.08
|
0.21
|
0.31
|
< 0.0001
|
|
HOMA-IR
|
0.04
|
0.59
|
− 0.17
|
0.014
|
0.14
|
0.084
|
0.083
|
0.39
|
0.19
|
0.003
|
0.35
|
< 0.0001
|
|
QUICKI
|
− 0.05
|
0.44
|
0.17
|
0.014
|
− 0.16
|
0.055
|
− 0.08
|
0.41
|
− 0.21
|
0.002
|
− 0.35
|
< 0.0001
|
|
HOMA-β
|
0.06
|
0.35
|
0.45
|
< 0.0001
|
− 0.25
|
0.002
|
− 0.1
|
0.31
|
− 0.46
|
<
0.0001
|
0.02
|
0.72
|
- Relative ratios of resistin/MCP-1, resistin/RBP4, visfatin/MCP-1, visfatin/SFRP5, MCP-1/RBP4, leptin/MCP-1 were calculated and correlated with insulin levels, and HOMA-IR, QUICKI and HOMA-β indexes. The correlations were calculated by using Spearman’s rank correlation coefficient. Spearman’s rho (ρ) and P values are presented
- HOMA-IR Homeostasis Model Assessment-Insulin Resistance, QUICKI Quantitative Insulin Sensitivity Check Index, HOMA-β homeostatic model assessment-β-cell function, HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol
